First seizure in the emergency department: stabilisation, provoked causes and disposition

Clinical scope and immediate priorities

A first seizure is an event requiring a cause-based assessment rather than an automatic diagnosis of epilepsy. The emergency clinician should stabilise the patient, determine whether the event was truly epileptic, identify acute provoked causes and recognise those needing urgent neurological investigation. Emergency care prioritises physiology and immediate threats before definitive diagnosis. Reassessment is essential because response to treatment, evolving symptoms and serial observations often provide more information than the initial snapshot. Clear escalation, handover and safety-netting reduce risk when diagnostic uncertainty remains.

Recognition and differential diagnosis

Obtain a witness history of onset, motor pattern, eye position, colour, tongue injury and recovery. Syncope can include brief jerking and should remain in the differential. Persistent focal deficit, prolonged confusion, fever, severe headache, pregnancy or trauma increases the likelihood of an acute intracranial or systemic cause. The practical aim is to identify features that change urgency, distinguish common mimics and avoid anchoring on a single test result. Where the presentation is atypical, reassess the working diagnosis rather than forcing the findings to fit it.

Assessment and investigations

Check glucose, electrolytes and pregnancy status where relevant, and review alcohol, recreational drugs and medications. Urgent CT is indicated for focal deficits, trauma, anticoagulation, persistent altered consciousness, immunosuppression or other intracranial risk. MRI and EEG are arranged urgently or as expedited follow-up depending on clinical risk. Investigations should be sequenced so that urgent bedside information is obtained first, followed by tests that refine cause, severity or treatment choice. Trends, prior results and treatment effects often matter more than whether one value sits just inside or outside a reference range.

Initial and definitive management

Treat active prolonged seizure as status epilepticus. Correct hypoglycaemia and major metabolic disturbance. Routine initiation of long-term antiseizure medication after every first unprovoked seizure is not required; treatment depends on recurrence risk, imaging/EEG findings, neurological disease and patient preference with specialist input. Treatment should address reversible causes and immediate physiological risk while preserving options for definitive care. Medication selection requires attention to allergies, interactions, renal or hepatic function, pregnancy where relevant, and the possibility that a medicine suitable in one health system may not be first-line in another.

Escalation, complications and special situations

Failure to return to baseline, recurrent seizures, suspected CNS infection, pregnancy-related seizure or focal neurological findings requires admission and specialist evaluation. Consider non-convulsive status when consciousness remains unexplained. Escalate early when instability, organ dysfunction, rapidly progressive symptoms or a high-risk comorbidity is present. Frailty, pregnancy, immunosuppression, extremes of age and major renal or hepatic impairment can alter both presentation and treatment tolerance, so protocol-based care still requires individualisation.

International practice across English-speaking health systems

Across the United Kingdom, United States, Canada, Australia, New Zealand and Ireland, the core clinical principles are broadly similar, but drug licensing, formularies, emergency pathways, screening thresholds, referral criteria and professional scope can differ. Use the most recent national or regional guidance, local antimicrobial or medicines policy, and the relevant product information when an operational detail could change treatment. MDPDA therefore presents a common evidence-based framework and highlights areas that should be adapted locally rather than implying that one country’s pathway is universal.

Monitoring, follow-up and prevention

Follow-up should be purposeful rather than routine. Define what is being monitored, when it should be reassessed and what finding would change management. Review adherence and adverse effects, repeat objective measurements when they inform risk, and reconsider the diagnosis if the clinical course is inconsistent with expectations. Safety-netting should state which symptoms require urgent reassessment and which service should be contacted. For chronic disease, prevention, vaccination where relevant, smoking cessation, nutrition, physical activity and management of related cardiovascular or metabolic risk can be as important as disease-specific treatment. Provide driving, bathing, heights and occupational safety advice according to local law, arrange neurology follow-up and explain recurrence precautions. Medication and substance contributors should be addressed directly.

Common pitfalls and safety checks

Brief convulsive movements do not prove epilepsy; syncope can produce jerks. Do not discharge a patient who has not returned to an appropriate baseline without understanding why. Long-term antiseizure treatment is not automatic after one unprovoked seizure. Driving advice is jurisdiction-specific and must be explicit. A useful final check is to ask what dangerous alternative diagnosis could still explain the presentation, whether the patient has demonstrated an appropriate response to treatment, and whether the discharge or transfer plan is safe if symptoms recur.

Documentation, communication and shared decisions

Documentation should make the clinical reasoning visible. Record the key positive and negative findings, relevant risk stratification, important investigations, treatment rationale, discussions with the patient or family where appropriate, and the trigger for escalation or review. When care crosses settings, handover should identify unresolved diagnostic questions, medicines started or withheld, pending results and who is responsible for follow-up. Shared decisions are particularly important when more than one reasonable strategy exists or when treatment benefit must be balanced against bleeding, frailty, treatment burden or quality of life.

Implementation across care settings

Emergency implementation is built around repeat observation. Record response to initial treatment, not just the first vital signs, and ensure pending tests or unresolved diagnostic uncertainty are handed over explicitly. Procedures and medicines should follow local resuscitation policy while preserving the same physiological priorities. Before discharge, confirm that the patient can access follow-up and understands precise return precautions. Where specialist services are distant, early consultation and transfer planning should occur in parallel with stabilisation rather than after deterioration.

Quality and patient-safety review

Before closing the episode of care, confirm that the working diagnosis remains consistent with the observed course, that high-risk alternatives have been considered, and that treatment has not introduced a new avoidable hazard. Review allergies, interactions, renal or hepatic constraints, pregnancy considerations where relevant, and the patient’s ability to follow the plan. The safest pathway is one in which the next clinician can understand what has been decided, what remains uncertain and which finding should trigger escalation.

Applying evidence to the individual patient

Guidelines provide a framework, but safe implementation depends on the patient’s baseline function, comorbidities, concurrent medicines, treatment goals and access to follow-up. Recommendations should be interpreted in light of absolute rather than relative benefit where possible, and clinicians should identify when the evidence base under-represents older people, pregnancy, severe kidney or liver impairment, multimorbidity or other groups. When two reasonable options exist, explain the trade-offs and document the reason for the selected approach. If local policy differs from an international recommendation, determine whether this reflects formulary, service configuration, licensing or genuinely different evidence. Reassessment is part of evidence-based care: a working diagnosis or treatment plan that no longer fits the clinical course should be revised rather than defended simply because it matched the initial pathway.

Practical review checklist

Before finalising management, confirm that the severity has been classified correctly, essential investigations have been acted on, and any test still pending has a named clinician or service responsible for review. Reconcile regular medicines and temporary changes, check whether monitoring is required after initiation or dose adjustment, and make the follow-up interval proportionate to risk. Explain the plan in language the patient can use, including what improvement is expected, which adverse effects matter and which symptoms require urgent help. Where care is shared between primary, secondary, dental, pharmacy or community services, avoid ambiguous instructions such as ‘follow up as needed’; specify who should do what and when. This final systems check often prevents harm that is not caused by the clinical decision itself but by gaps in implementation.